Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma

Su, Hengchuan; Wang, Hongkai; Shi, Guohai; Zhang, Ye; Sun, Fenyong; Ye, Dingwei

doi:10.1016/j.ejso.2018.01.013

Cited by 9 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lung cancer associated transcript 1 (LUCAT1), [10,11] promoter of CDKN1A antisense DNA damage activated RNA (PANDAR), [12] plasmacytoma variant translocation 1 (PVT1), [13,14] metastatic renal cell carcinoma-associated transcript 1 (MRCCAT1), [15] linc00152, [16] lncRNA H19, [17] metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), [18,19] protein sprouty homolog 4 intronic transcript-1 (SPRY4-IT1) [20] were up-regulated. And ENSG241684, [21] NONHSAT123350, [22] lnc-ZNF180-2, [23] neuroblastoma associated transcript-1 (NBAT1), [24] and cell adhesion molecule 1 anti-sense transcript-1 (CADM1-AS1) [25] were down-regulated. None of these studies clarified that these lncRNAs were related to gender and age of ccRCC patients.…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma

Wang

Zhan

et al. 2019

Medicine

View full text Add to dashboard Cite

Background:Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer in adults, and patients with advanced ccRCC have a 5-year survival rate of <30%. The poor prognosis of ccRCC is closely related to its lacking of potential therapeutic and prognostic biomarkers. This meta-analysis aimed to elucidate the precise prognostic value of long non-coding RNAs (lncRNAs) in patients with ccRCC.Methods:A literature search was performed in related databases up to January 31, 2019. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated to explore the relationship between special lncRNAs expression and survival in patients with ccRCC.Results:After literature researching, a total of 16 studies, including 13 lncRNAs were identified. The data from studies that investigated the association between lncRNA expression and survival outcomes in patients with ccRCC were extracted. Results revealed that lncRNAs expression was significantly associated with poor overall survival (OS) outcome in patients with ccRCC (HR = 1.71, 95%CI = 1.40–2.01 in up-regulated subgroup; HR = 0.53, 95% CI = 0.25–0.80 in down-regulated subgroup). The overexpression of PVT1 was significantly associated with poor OS in ccRCC (HR = 1.51, 95% CI = 1.02–2.00). Meanwhile, up-regulation of LUCAT1 was significantly related to worse OS in ccRCC patients (HR = 1.51, 95% CI = 1.01–2.00).Conclusions:These results suggest that lncRNAs could be used to predict unfavorable prognosis and function as potential prognostic biomarkers in ccRCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma

Wang

Zhan

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Previous researches have reported that ADAMTS9-AS2 was down-regulated in colorectal cancer, clear cell renal cell carcinoma, lung cancer and glioma. [23][24][25][26][27] Moreover, ADAMTS9-AS2 expression was negatively correlated with the survival of these cancers. miR-32 is a tumour-associated microRNA, but its role in cancer is contradictory.…”

Section: Discussionmentioning

confidence: 97%

Identification and development of long non‐coding RNA‐associated regulatory network in colorectal cancer

Pan

Song

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the leading causes of cancer‐associated death globally. Long non‐coding RNAs (lncRNAs) have been identified as micro RNA (miRNA) sponges in a competing endogenous RNA (ceRNA) network and are involved in the regulation of mRNA expression. This study aims to construct a lncRNA‐associated ceRNA network and investigate the prognostic biomarkers in CRC. A total of 38 differentially expressed (DE) lncRNAs, 23 DEmiRNAs and 27 DEmRNAs were identified by analysing the expression profiles of CRC obtained from The Cancer Genome Atlas (TCGA). These RNAs were chosen to develop a ceRNA regulatory network of CRC, which comprised 125 edges. Survival analysis showed that four lncRNAs, six miRNAs and five mRNAs were significantly associated with overall survival. A potential regulatory axis of ADAMTS9‐AS2/miR‐32/PHLPP2 was identified from the network. Experimental validation was performed using clinical samples by quantitative real‐time PCR (qRT‐PCR), which showed that expression of the genes in the axis was associated with clinicopathological features and the correlation among them perfectly conformed to the ‘ceRNA theory’. Overexpression of ADAMTS9‐AS2 in colon cancer cell lines significantly inhibited the miR‐32 expression and promoted PHLPP2 expression, while ADAMTS9‐AS2 knockdown had the opposite effects. The constructed novel ceRNA network may provide a comprehensive understanding of the mechanisms of CRC carcinogenesis. The ADAMTS9‐AS2/miR‐32/PHLPP2 regulatory axis may serve as a potential therapeutic target for CRC.

show abstract

“…The lncRNA ADAMTS9-AS2 is the antisense transcript of tumor suppressor ADAMTS9, and it is considered as a novel tumor suppressor. Previous studies have showed that expression of ADAMTS9-AS2 was downregulated in various cancers (30–34). Additionally, ADAMTS9-AS2 expression was associated with the poor survival outcomes of these cancers.…”

Section: Discussionmentioning

confidence: 98%

Construction of a Competitive Endogenous RNA Network and Identification of Potential Regulatory Axis in Gastric Cancer

et al. 2019

View full text Add to dashboard Cite

Background: Increasing studies has found that long non-coding RNAs (lncRNAs) play critical roles in carcinogenesis, but the underlying mechanisms remain unclear. The aim of this study is to construct a competitive endogenous RNA (ceRNA) network and to identify potential regulatory axis in gastric cancer (GC).Methods: Differentially expressed (DE) mRNAs, miRNAs, and lncRNAs were obtained by analyzing the RNA expression profiles of stomach adenocarcinoma (STAD) retrieved from The Cancer Genome Atlas (TCGA) database. The lncRNA-miRNA-mRNA regulatory networks of GC were constructed by comprehensive bioinformatics methods including functional annotation, RNA-RNA interactomes prediction, correlation analysis, and survival analysis. The interactions and correlations among ceRNAs were validated by experiments on cancer tissues and cell lines.Results: A total of 41 lncRNAs, 9 miRNAs, and 10 mRNAs were identified and selected to establish the ceRNA regulatory network of GC. Several ceRNA regulatory axes, which consist of 18 lncRNAs, 4 miRNAs, and 6 mRNAs, were obtained from the network. A potential ADAMTS9-AS2/miR-372/CADM2 axis which perfectly conformed to the ceRNA theory was further analyzed. qRT-PCR showed that ADAMTS9-AS2 knockdown remarkably increased miR-372 expression but reduced CADM2 expression, whereas ADAMTS9-AS2 overexpression had the opposite effects. Dual luciferase reporter assay indicated that miR-372 could bound to the ADAMTS9-AS2 and the 3′UTR of CADM2.Conclusion: The constructed novel ceRNA network and the potential regulatory axes might provide a novel approach of the exploring the potential mechanisms of development in GC. The ADAMTS9-AS2/miR-372/CADM2 could act as a promising target for GC treatment.

show abstract

Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma

Cited by 9 publications

References 17 publications

Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma

Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma

Identification and development of long non‐coding RNA‐associated regulatory network in colorectal cancer

Construction of a Competitive Endogenous RNA Network and Identification of Potential Regulatory Axis in Gastric Cancer

Contact Info

Product

Resources

About